Signal transduction and oncogenesis by ErbB/HER receptors.
暂无分享,去创建一个
[1] O. Segatto,et al. Negative regulation of receptor tyrosine kinase signals , 2001, FEBS letters.
[2] M. Lisanti,et al. Interaction of a Receptor Tyrosine Kinase, EGF-R, with Caveolins , 1997, The Journal of Biological Chemistry.
[3] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[4] Richard J. Lee,et al. Reciprocal Regulation of Neu Tyrosine Kinase Activity and Caveolin-1 Protein Expression in Vitro and in Vivo , 1998, The Journal of Biological Chemistry.
[5] M. Lisanti,et al. Caveolins in cholesterol trafficking and signal transduction: implications for human disease. , 2000, Frontiers in bioscience : a journal and virtual library.
[6] Yosef Yarden,et al. Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.
[7] A. Thomason,et al. Transformation of NIH 3T3 Cells by HER3 or HER4 Receptors Requires the Presence of HER1 or HER2 (*) , 1996, The Journal of Biological Chemistry.
[8] B. Hemmings,et al. Regulation of protein kinase B. , 1999, Journal of receptor and signal transduction research.
[9] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.
[10] M. Sliwkowski,et al. Binding specificities and affinities of egf domains for ErbB receptors , 1999, FEBS letters.
[11] P. Humphrey,et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[12] Richard G. W. Anderson,et al. Localization of Epidermal Growth Factor-stimulated Ras/Raf-1 Interaction to Caveolae Membrane (*) , 1996, The Journal of Biological Chemistry.
[13] M. Denton,et al. Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor , 2001, Oncogene.
[14] H. Esumi,et al. Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers. , 2002, Molecular biology of the cell.
[15] Rüdiger Klein,et al. Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor , 1995, Nature.
[16] T. Hunter,et al. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. , 1999, Science.
[17] M. Lemmon,et al. The Single Transmembrane Domains of ErbB Receptors Self-associate in Cell Membranes* , 2002, The Journal of Biological Chemistry.
[18] S. Courtneidge,et al. Src family tyrosine kinases and growth factor signaling. , 2000, Experimental cell research.
[19] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[20] Yosef Yarden,et al. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors , 1997, Oncogene.
[21] O. Feron,et al. Neuregulin signaling in the heart. Dynamic targeting of erbB4 to caveolar microdomains in cardiac myocytes. , 1999, Circulation research.
[22] D. Johnston,et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] H. Wiley,et al. ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.
[24] Y. Yarden,et al. c-Cbl Is a Suppressor of the Neu Oncogene* , 2000, The Journal of Biological Chemistry.
[25] A. Burgess,et al. Structure-Function relationships for the EGF/TGF-α family of mitogens , 1994 .
[26] M. Komada,et al. Hrs and hbp: possible regulators of endocytosis and exocytosis. , 2001, Biochemical and biophysical research communications.
[27] J. Pierce,et al. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene , 1990, Molecular and cellular biology.
[28] B. Shilo,et al. Sprouty is a general inhibitor of receptor tyrosine kinase signaling. , 1999, Development.
[29] S. Parsons,et al. c-Src, receptor tyrosine kinases, and human cancer. , 1999, Advances in cancer research.
[30] A. Lenferink,et al. Differential endocytic routing of homo‐ and hetero‐dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers , 1998, The EMBO journal.
[31] A. Berezov,et al. HER2/Neu: mechanisms of dimerization/oligomerization , 2002, Oncogene.
[32] G. Carpenter. Employment of the Epidermal Growth Factor Receptor in Growth Factor–Independent Signaling Pathways , 1999, The Journal of cell biology.
[33] N. Normanno,et al. Epidermal growth factor-related peptides and their receptors in human malignancies. , 1995, Critical reviews in oncology/hematology.
[34] N. Maihle,et al. The EGF/ErbB Receptor Family and Apoptosis , 2002, Growth factors.
[35] R. G. Anderson. The caveolae membrane system. , 1998, Annual review of biochemistry.
[36] Paul W. Sternberg,et al. The let-23 gene necessary for Caenorhabditis elegans vulval induction encodes a tyrosine kinase of the EGF receptor subfamily , 1990, Nature.
[37] Yosef Yarden,et al. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer , 2000, Oncogene.
[38] Yong Liao,et al. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.
[39] L. Theill,et al. Neuregulins with an Ig-like domain are essential for mouse myocardial and neuronal development. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[40] L. Cantley,et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[41] D A Lauffenburger,et al. Intracellular Trafficking of Epidermal Growth Factor Family Ligands Is Directly Influenced by the pH Sensitivity of the Receptor/Ligand Interaction (*) , 1995, The Journal of Biological Chemistry.
[42] D. W. Fry,et al. Anticancer therapy targeting the erbB family of receptor tyrosine kinases. , 2001, Seminars in oncology.
[43] Y. Yarden,et al. ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. , 1996, The EMBO journal.
[44] M. Freeman,et al. Inhibition of Drosophila EGF receptor activation by the secreted protein Argos , 1995, Nature.
[45] Hyun-soo Cho,et al. Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether , 2002, Science.
[46] Carmen Birchmeier,et al. Multiple essential functions of neuregulin in development , 1995, Nature.
[47] L. Cantley,et al. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[48] M. Hung,et al. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies , 2000, Oncogene.
[49] R H Perry,et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.
[50] Boon Chuan Low,et al. Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling , 2002, The EMBO journal.
[51] J. Brugge,et al. Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.
[52] M. Freeman,et al. Complexity of EGF receptor signalling revealed in Drosophila. , 1998, Current opinion in genetics & development.
[53] M. Lemmon,et al. Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.
[54] G. Sala,et al. Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control , 2002, Oncogene.
[55] Richard G. W. Anderson,et al. Regulated Migration of Epidermal Growth Factor Receptor from Caveolae* , 1999, The Journal of Biological Chemistry.
[56] Jun Yao,et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. , 1998, Molecular cell.
[57] John M. Daly,et al. ErbB2 Potentiates Breast Tumor Proliferation through Modulation of p27Kip1-Cdk2 Complex Formation: Receptor Overexpression Does Not Determine Growth Dependency , 2000, Molecular and Cellular Biology.
[58] P. Sternberg,et al. ARK-1 inhibits EGFR signaling in C. elegans. , 2000, Molecular cell.
[59] D. Bigner,et al. Molecular pathogenesis of malignant gliomas. , 1999, Current opinion in oncology.
[60] K. Carraway,et al. Neuregulins and their receptors , 1995, Current Opinion in Neurobiology.
[61] M. Hung,et al. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells , 2001, Nature Cell Biology.
[62] L. Cantley,et al. p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*) , 1996, The Journal of Biological Chemistry.
[63] Y. Yarden,et al. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network , 1998, The EMBO journal.
[64] Y. Yarden,et al. The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma-derived growth factors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[65] H. Modjtahedi,et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. , 2000, Cancer research.
[66] S. Hubbard,et al. Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.
[67] L. Cantley,et al. Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer* , 2000, The Journal of Biological Chemistry.
[68] N. Perrimon,et al. The Transmembrane Molecule Kekkon 1 Acts in a Feedback Loop to Negatively Regulate the Activity of the Drosophila EGF Receptor during Oogenesis , 1999, Cell.
[69] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[70] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[71] Yosef Yarden,et al. Biology of HER2 and Its Importance in Breast Cancer , 2001, Oncology.
[72] Kuo-Fen Lee,et al. Requirement for neuregulin receptor erbB2 in neural and cardiac development , 1995, Nature.
[73] H. Lee,et al. EGF/ErbB receptor family in ovarian cancer. , 2002, Cancer treatment and research.
[74] A. Ullrich,et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. , 2001, Endocrine-related cancer.
[75] M. Sliwkowski,et al. A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 Is Required for Transactivation of ErbB2* , 1999, The Journal of Biological Chemistry.
[76] J. Ross,et al. The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.
[77] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[78] A. Wells,et al. Signalling shortcuts: cell-surface receptors in the nucleus? , 2002, Nature Reviews Molecular Cell Biology.
[79] Monilola A. Olayioye,et al. The ErbB receptor tyrosine family as signal integrators. , 2001, Endocrine-related cancer.
[80] G. Carpenter,et al. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired. , 1993, Oncogene.
[81] S. Aaronson,et al. The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. , 1990, The New biologist.
[82] S. Aaronson,et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene , 1988, Molecular and cellular biology.
[83] A Ciechanover,et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. , 1999, Molecular cell.
[84] Y. Yarden,et al. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. , 1996, Oncogene.
[85] Jae-Hoon Kim,et al. Crystal Structure of the Complex of Human Epidermal Growth Factor and Receptor Extracellular Domains , 2002, Cell.
[86] M. Kraus,et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. , 1995, Oncogene.
[87] R. Kumar,et al. The role of HER2 in angiogenesis. , 2001, Seminars in oncology.
[88] Y. Yarden,et al. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. , 2000, Cancer research.
[89] R. Weinberg,et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.
[90] M. Roussel,et al. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. , 1998, Genes & development.
[91] Monilola A. Olayioye,et al. ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner , 1998, Molecular and Cellular Biology.
[92] Edouard C. Nice,et al. Crystal Structure of a Truncated Epidermal Growth Factor Receptor Extracellular Domain Bound to Transforming Growth Factor α , 2002, Cell.
[93] J. Engelman,et al. Targeted downregulation of caveolin‐1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade , 1998, The EMBO journal.
[94] I. Lorimer. Mutant epidermal growth factor receptors as targets for cancer therapy. , 2002, Current cancer drug targets.
[95] L. Neckers,et al. Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.
[96] J. Biegel,et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. , 1995, Cancer research.
[97] M. Sliwkowski,et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.
[98] A. Ullrich,et al. Smart drugs: tyrosine kinase inhibitors in cancer therapy. , 2002, Cancer cell.
[99] J. Massagué,et al. Membrane-anchored growth factors. , 1993, Annual review of biochemistry.
[100] Y. Yarden,et al. Cyclin D1 Is Required for Transformation by Activated Neu and Is Induced through an E2F-Dependent Signaling Pathway , 2000, Molecular and Cellular Biology.
[101] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[102] B. Geiger,et al. Alternative Intracellular Routing of ErbB Receptors May Determine Signaling Potency* , 1998, The Journal of Biological Chemistry.
[103] R. Neve,et al. Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells , 2000, Oncogene.
[104] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[105] R. Ward,et al. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines , 2001, Cancer Immunology, Immunotherapy.
[106] H. P. Fell,et al. The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 Cells* , 1996, The Journal of Biological Chemistry.
[107] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[108] A. Ullrich,et al. Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission , 2001, Oncogene.
[109] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[110] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[111] N. Normanno,et al. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs): Simple drugs with a complex mechanism of action? , 2003, Journal of cellular physiology.
[112] T. Pawson,et al. SH2 domains recognize specific phosphopeptide sequences , 1993, Cell.
[113] M. Lisanti,et al. Caveolin-1, a putative tumour suppressor gene. , 2001, Biochemical Society transactions.
[114] H. Poulsen,et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[115] G. Hortobagyi,et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol , 1998, Oncogene.
[116] D. Bigner,et al. EGFRvIII as a promising target for antibody-based brain tumor therapy , 2006, Brain Tumor Pathology.
[117] K. Makino,et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.
[118] M. Crescenzi,et al. Inhibition of ErbB-2 Mitogenic and Transforming Activity by RALT, a Mitogen-Induced Signal Transducer Which Binds to the ErbB-2 Kinase Domain , 2000, Molecular and Cellular Biology.
[119] M. Sliwkowski,et al. Perspectives on Anti-HER Monoclonal Antibodies , 2002, Oncology.
[120] Lucas Pelkmans,et al. Endocytosis Via Caveolae , 2002, Traffic.
[121] C R King,et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.
[122] M. Sliwkowski,et al. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. , 2001, Cancer research.
[123] A. Berezov,et al. HER2/Neu: mechanisms of dimerization/oligomerization , 2000, Oncogene.
[124] G. Carpenter,et al. All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired (*) , 1996, The Journal of Biological Chemistry.
[125] T. van Raaij,et al. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family , 1995, Molecular and cellular biology.
[126] N. Rosen,et al. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. , 2002, Cancer research.
[127] Y. Yarden,et al. Molecular mechanisms underlying endocytosis and sorting of ErbB receptor tyrosine kinases , 2001, FEBS letters.
[128] S. Sharpe,et al. Interaction between ErbB‐1 and ErbB‐2 transmembrane domains in bilayer membranes , 2002, FEBS letters.
[129] R. Cardiff,et al. Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.
[130] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[131] Richard G. W. Anderson,et al. Cholesterol Depletion of Caveolae Causes Hyperactivation of Extracellular Signal-related Kinase (ERK)* , 1998, The Journal of Biological Chemistry.